{
  "id": "5c71d7ca7c78d6947100006b",
  "type": "factoid",
  "question": "Erenumab, used to treat migraine headaches, binds to what protein?",
  "ideal_answer": "Erenumab binds to the CGRP receptor to treat migraine headaches",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28835404",
    "http://www.ncbi.nlm.nih.gov/pubmed/28736918",
    "http://www.ncbi.nlm.nih.gov/pubmed/30242830",
    "http://www.ncbi.nlm.nih.gov/pubmed/29432219",
    "http://www.ncbi.nlm.nih.gov/pubmed/30360965",
    "http://www.ncbi.nlm.nih.gov/pubmed/29691490",
    "http://www.ncbi.nlm.nih.gov/pubmed/29471679",
    "http://www.ncbi.nlm.nih.gov/pubmed/29171821",
    "http://www.ncbi.nlm.nih.gov/pubmed/30074549",
    "http://www.ncbi.nlm.nih.gov/pubmed/29697153",
    "http://www.ncbi.nlm.nih.gov/pubmed/30409109",
    "http://www.ncbi.nlm.nih.gov/pubmed/29968151",
    "http://www.ncbi.nlm.nih.gov/pubmed/30086681"
  ],
  "snippets": [
    {
      "text": "Monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) signaling are being explored as prophylactic treatments for migraine. Erenumab (AMG 334) is the first potent, selective, and competitive human mAb antagonist of the CGRP receptor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28736918",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Monoclonal antibodies (mAbs) targeting the calcitonin-gene-related peptide (CGRP) pathway have been developed for episodic and chronic migraine prevention, either through binding the CGRP ligand (eptinezumab, fremanezumab, galcanezumab) or the CGRP receptor (erenumab).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29432219",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab). To date, these monoclonal antibodies have shown promising efficacy in clinical trials, with no major safety concerns. If ongoing long-term studies show that their efficacy can be maintained, this may herald a new era for effective antimigraine therapies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29697153",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\nMigraine prevention with erenumab and\u00a0migraine induction by calcitonin gene-related peptide (CGRP) both carry notable individual variance.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30409109",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Background We evaluated the effect of erenumab, a fully human monoclonal antibody that inhibits the canonical calcitonin gene-related peptide receptor, on migraine-related disability, impact, and health-related quality of life among patients with episodic migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30086681",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Erenumab is a novel CGRP-receptor antibody with preventive efficacy in migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30360965",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Results - The US Food and Drug Administration (FDA) approved erenumab, an anti-CGRP receptor monoclonal antibody, for prevention of migraine May 17, 2018.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30242830",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Erenumab, a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29471679",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\nWe tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29171821",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In addition, erenumab, a calcitonin gene-related peptide (CGRP) receptor monoclonal antibody, received approval from the US Food and Drug Administration (FDA) for the prevention of migraine in May 2018.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30074549",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CGRP receptor antagonists such as ubrogepant are effective for acute relief of migraine headache, whereas monoclonal antibodies against CGRP (eptinezumab, fremanezumab and galcanezumab) or the CGRP receptor (erenumab) effectively prevent migraine attacks.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29691490",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Amgen and Novartis are developing erenumab (AIMOVIG\u2122, erenumab-aooe)-a fully human monoclonal antibody calcitonin gene-related peptide (CGRP) receptor antagonist-for the prevention of migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29968151",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND We tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29171821",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE To assess long-term safety and efficacy of anti-calcitonin gene-related peptide receptor erenumab in patients with episodic migraine (EM).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28835404",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "CGRP receptor"
}